Journalartikel
Autorenliste: Roll, Petra; Ostermeier, Eva; Haubitz, Marion; Lovric, Svjetlana; Unger, Leonore; Holle, Julia; Koetter, Ina; Henes, Joerg C.; Bergner, Raoul; Rubbert-Roth, Andrea; Specker, Christof; Schulze-Koops, Hendrik; Mueller-Ladner, Ulf; Fleck, Martin; Burmester, Gerd-Ruediger; Hiepe, Falk; Heitmann, Stefan; Aringer, Martin; Fischer-Betz, Rebecca; Doerner, Thomas; Tony, Hans-Peter
Jahr der Veröffentlichung: 2012
Seiten: 2153-2156
Zeitschrift: The Journal of Rheumatology
Bandnummer: 39
Heftnummer: 11
ISSN: 0315-162X
Open Access Status: Bronze
DOI Link: https://doi.org/10.3899/jrheum.120482
Verlag: The Journal of Rheumatology
Objective. Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV. Methods. Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry. Results. In total, 58 patients were included in this analysis (50/58 with granulomatosis with polyangiitis; 8/58 with microscopic polyangiitis who received at least I cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40%) and in 29 cases (52.7%), respectively. Four patients (7.3%) were classified as nonresponders. Conclusion. RTX was well tolerated with good clinical efficacy in patients with refractory AAV. (First Release Sept 15 2012; J Rheumatol 2012;39:2153-6; doi:10.3899/jrheum.120482)
Abstract:
Zitierstile
Harvard-Zitierstil: Roll, P., Ostermeier, E., Haubitz, M., Lovric, S., Unger, L., Holle, J., et al. (2012) Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID), The Journal of Rheumatology, 39(11), pp. 2153-2156. https://doi.org/10.3899/jrheum.120482
APA-Zitierstil: Roll, P., Ostermeier, E., Haubitz, M., Lovric, S., Unger, L., Holle, J., Koetter, I., Henes, J., Bergner, R., Rubbert-Roth, A., Specker, C., Schulze-Koops, H., Mueller-Ladner, U., Fleck, M., Burmester, G., Hiepe, F., Heitmann, S., Aringer, M., Fischer-Betz, R., ...Tony, H. (2012). Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID). The Journal of Rheumatology. 39(11), 2153-2156. https://doi.org/10.3899/jrheum.120482
Schlagwörter
ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIDES; CYCLOPHOSPHAMIDE; RITUXIMAB; WEGENERS-GRANULOMATOSIS
